Additionally, the combination of T-DXd with pembrolizumab is currently under investigation in an ongoing phase Ib trial, targeting patients with HER2-expressing advanced/mBC or NSCLC [82]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.